SAN FRANCISCO and CHICAGO, Jan. 12, 2026 /PRNewswire/ -- Cytovale ®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune ...

New multicenter analysis highlights IntelliSep's clinical usability and impact on frontline physician decision-making, strengthening existing real-world evidence SAN FRANCISCO, March 30, 2026 ...

Cytovale Inc. has posted a feverish run of wins lately. The company gained U.S. FDA clearance for its Intellisep rapid test for sepsis in January 2023, raised $84 million in a series C in November and ...

Data Published in Journal PLOS ONE Demonstrates Investigational IntelliSep test may Provide Useful Prognostic Information for Patients with Suspected Infection SAN FRANCISCO--(BUSINESS WIRE)--Cytovale ...

SAN FRANCISCO and CHICAGO, March 23, 2026 /PRNewswire/ -- Cytovale® today announced new multicenter, real-world data demonstrating that clinical and operational improvements in sepsis care first ...

SAN FRANCISCO--(BUSINESS WIRE)--Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune mediated diseases, today announced the ...

Critical care physician Hollis O'Neal, MD, MSc, Associate Professor of Medicine at LSU Health New Orleans School of Medicine's Baton Rouge campus, presented data that validate a rapid diagnostic test ...

Sepsis is the leading cause of death worldwide according to the World Health Organization, killing 11 million people each year, many of them children, and disabling many more. But while speedy ...

SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- A new peer-reviewed study published in JACEP Open found that providing emergency department (ED) physicians with IntelliSep(R) sepsis test results was ...

Cytovale's IntelliSep ® rapid sepsis test spotlighted for its innovative approach to sepsis care and demonstrated real-world impact in helping hospitals save lives SAN FRANCISCO and CHICAGO, Jan. 12, ...